VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
2.320
+0.030 (1.31%)
At close: Dec 5, 2025, 4:00 PM EST
2.280
-0.040 (-1.72%)
After-hours: Dec 5, 2025, 7:58 PM EST
VivoSim Labs Revenue
VivoSim Labs had revenue of $28.00K in the quarter ending September 30, 2025, a decrease of -6.67%. This brings the company's revenue in the last twelve months to $140.00K, up 35.92% year-over-year. In the fiscal year ending March 31, 2025, VivoSim Labs had annual revenue of $144.00K with 32.11% growth.
Revenue (ttm)
$140.00K
Revenue Growth
+35.92%
P/S Ratio
34.14
Revenue / Employee
$10,769
Employees
13
Market Cap
6.05M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VIVS News
- 4 months ago - VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer - GlobeNewsWire
- 7 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 7 months ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 7 months ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire
- 8 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 8 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 8 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 9 months ago - Organovo Provides Business Update - GlobeNewsWire